Event-Driven Stocks

Terns Pharmaceuticals, Inc.

TERNNasdaq

Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕

View price & chart on Yahoo Finance ↗
Signs● 3 good● 1 warningdetails ↓

Financials

SEC XBRL · annual
 FY25FY24FY23FY22FY21FY20
Revenue———$0$1.0M$0
Operating income−$110.1M−$101.9M−$102.6M−$62.0M−$49.9M−$37.0M
Net income−$96.2M−$88.9M−$90.2M−$60.3M−$50.2M−$40.1M
Total assets$1.03B$363.9M$268.5M$287.0M$168.1M$92.3M
Total liabilities$18.6M$18.1M$13.2M$10.1M$7.8M$23.7M
Equity$1.01B$345.9M$255.4M$276.9M$160.3M−$117.4M
EPS (diluted)$-1.03$-1.12$-1.27$-1.67$-2.21—
Shares out.87.3M64.7M56.7M25.3M25.3M337,508

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2025
Operating margin
—
Net margin
—
Return on equity
−9.6%
Return on assets
−9.4%
Return on capital (ROCE)
−10.9%
Liabilities / assets
1.8%
Debt / equity
0.02×
Book value / share
$11.53
Revenue growth (YoY)
—
Net income growth (YoY)
—

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2025
Altman Z″ (distress)
61.04safe
Accruals / assets
−1.4%clean
Piotroski F-Score
4/7mixed

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
50
/ 100
Profitability 0Growth n/aCatalyst 33Earnings quality 67Financial strength 100

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.

Signs

● 1 warning● 3 good
  • Negative operating cash flow
  • Conservative leverage (liabilities < 50% of assets)
  • Clean earnings (low accruals)
  • Altman Z″ in the safe zone

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

Clinical trials

ClinicalTrials.gov · ongoing · next readout first

Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.

Insider transactions

SEC Form 4 · most recent
0 acquisitions1 disposalsnet −24,562 shares · last 1
InsiderDateTypeSharesPrice
Kuriakose EmilOfficer — Chief Medical OfficerMay 5, 2026U24,562$53.00

Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.

Short interest

FINRA · bi-monthly
SettlementShares shortDays to coverΔ vs prior
Apr 30, 20265.5M1.5-31.3%
Apr 15, 20268.1M1.0-40.3%
Mar 31, 202613.5M1.1-25.8%
Mar 13, 202618.2M8.7+9.5%
Feb 27, 202616.6M8.7-10.7%

Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Event-driven situations (3)